French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome
← catalyst calendarNCT05308927 · readout in 576 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
221estimated
Sites
3
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-16 | actual | When the study began enrolling |
| Primary completion | 2028-03-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-17 | estimated | The whole study's end, after follow-up |
| First posted | 2022-04-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Noonan Syndrome
Intervention
- Drug: Norditropin — also filed as Somatropin
Primary outcome
what the primary-completion date above is the date OFChange in height standard deviation score
measured From start of Norditropin® treatment (day 0) until end of follow-up (up to 6 years)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed